Treatment non-persistence in children and adolescents with Tourette syndrome newly treated with dopamine D2 receptor modulators (opens in new tab)

IntroductionDopamine D2 receptor antagonists/partial agonists (D2RAs), including the US Food and Drug Administration–approved Tourette syndrome (TS) agents haloperidol, pimozide, and aripiprazole and other antipsychotics with dopamine D2 receptor–modulating properties, are prescribed for TS. This retrospective real-world study compared adverse events (AEs) and health care resource utilization (HCRU) between pediatric patients with TS newly treated versus not treated with D2RAs.MethodsData wer...